ClinicalTrials HQ

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Recruiting · NCT05394103 · Registry updated 2025-08-17
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid TumorsNeoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasmRecruitingPhase 1 / Phase 22025-08-17NCT05394103

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Merck Sharp & Dohme LLC650
Qurient Co., Ltd.4

11 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Asan Medical CenterSeoulSouth Korea131
Atlantic Health System HospitalMorristownUnited States1
CHA University Bundang Medical CenterSeongnam-siSouth Korea1
Mary Crowley Cancer ResearchDallasUnited States29
Mayo ClinicRochesterUnited States664
Mayo ClinicPhoenixUnited States50
Mayo ClinicJacksonvilleUnited States122
National Cancer CenterGoyang-siSouth Korea23
Northwestern UniversityChicagoUnited States727
Severance HospitalSeoulSouth Korea62
University of Southern CaliforniaLos AngelesUnited States110